Horm Metab Res 2006; 38(1): 57-59
DOI: 10.1055/s-2006-924980
Short Communication
© Georg Thieme Verlag KG Stuttgart · New York

Absorption Kinetics of Levothyroxine Is Not Altered by Proton-pump Inhibitor Therapy

J.  W.  Dietrich1, 2 , K.  Gieselbrecht2 , R.  W.  Holl3 , B.  O.  Boehm2
  • 1Medical Clinic I, Endocrinology and Diabetology, Bergmannsheil Hospitals, Ruhr University Clinics, Bochum, Germany
  • 2Department of Internal Medicine I, Ulm University, Ulm, Germany
  • 3Central Institute for Biomedical Engineering, Ulm University, Germany
Weitere Informationen

Publikationsverlauf

Received 4 May 2005

Accepted after revision 8 August 2005

Publikationsdatum:
13. Februar 2006 (online)

Introduction

Iodothyronines are widely prescribed drugs in developed countries. Several studies have shown a high prevalence of hypothyroidism in unselected populations [1]. In view of the frequency and comparatively small therapeutic range of thyroid hormones, interactions with other drugs are of considerable importance. The absorption of iodothyronines is known to be influenced by numerous substances, including antacid drugs [2] [3]. Sufficient gastric acidity has been assumed to be a prerequisite for effective iodothyronine resorption as a result [4]. However, whether thyroid replacement therapy is disturbed in patients treated with proton-pump inhibitors is still unknown, although this most effective form of acid inhibition is increasingly prescribed. To address this question, we have conducted a study in order to answer the question as to whether proton-pump inhibition affects levothyroxine resorption.

References

  • 1 Canaris G J, Manowitz N R, Mayor G, Ridgway E C. .  Arch Intern Med. 2000;  160 526-534
  • 2 Surks M I, Sievert R. .  New Engl J Med. 1995;  333 (25) 1688-1694
  • 3 Sperber A D, Liel Y. .  Arch Intern Med. 1992;  152 183-184
  • 4 Klein I, Danzi S. .  Thyroid. 2003;  13 1127-1132
  • 5 Campbell N R, Hasinoff B B, Stalts H, Rao B, Wong N C. .  Ann Intern Med. 1992;  117 1010-1013
  • 6 Singh N, Weisler S L, Hersman J M. .  Thyroid. 2001;  11 967-971
  • 7 Berg J A, Mayor G H. .  J Clin Pharmacol. 1993;  33 1135-1140
  • 8 Krehan A, Dittmar M, Hoppen A, Lichtwald K, Kahaly G J. .  Medizinische Klinik. 2002;  97 522-527
  • 9 Evenepoel P, Claus D, Geypens B. et al . .  Aliment Pharmacol Ther. 1998;  12 1011-1019
  • 10 Marcuard S P, Albernaz L, Khazanie P G. .  Ann Intern Med. 1994;  120 211-215
  • 11 Hays M T. .  Endocrine Research. 1988;  14 203-224
  • 12 Krenning E P, Docter R, Visser T J, Hennemann G. .  Acta medica Austriaca. 1988;  15 (Suppl 1) 15-17
  • 13 Hennemann G, Docter R, Friesema E C, de Jong M, Krenning E P, Visser T J. .  Endocr Rev. 2001;  22 451-476
  • 14 Harmon S M, Seifert C F. .  Ann Intern Med. 1993;  118 112-113

Prof. Bernhard O. Boehm, M. D.

Division of Endocrinology and Diabetes · Ulm University ·

Robert-Koch-Straße 8 · 89081 Ulm · Germany

Telefon: +49 (731) 500-24 304 ·

Fax: +49 (731) 500-23 938

eMail: bernhard.boehm@medizin.uni-ulm.de